Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...
The PSO-1 (Pritsel Snaipersky Optichesky, "Optical Sniper Sight") is a Russian scope with 4x magnification compared to the iron sights. The PSO-1 (4x) falls in the Optics Category of the Weapon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results